Acurx Pharmaceuticals Inc (ACXP)
2.17
+0.05
(+2.36%)
USD |
NASDAQ |
May 03, 16:00
2.17
0.00 (0.00%)
After-Hours: 20:00
Acurx Pharmaceuticals Cash from Financing (Quarterly): 4.620M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.620M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 3.544M |
| March 31, 2023 | |
| December 31, 2022 | -0.00 |
| September 30, 2022 | 3.695M |
| June 30, 2022 | 0.00 |
| March 31, 2022 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 14.80M |
| March 31, 2021 | |
| December 31, 2020 | 0.7285M |
| September 30, 2020 | 2.191M |
| June 30, 2020 | 1.124M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2022
14.80M
Maximum
Jun 2021
2.362M
Average
0.7285M
Median
Dec 2020
Cash from Financing (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 40.71M |
| Seelos Therapeutics Inc | 2.323M |
| PetVivo Holdings Inc | 1.502M |
| NovaBay Pharmaceuticals Inc | -0.026M |
| Palatin Technologies Inc | 4.974M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.198M |
| Free Cash Flow | -9.801M |
| Free Cash Flow Per Share (Quarterly) | -0.3033 |
| Free Cash Flow Yield | -35.65% |